CoChat

Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Background and Objective: There are currently no drugs approved to treat vascular dementia (VaD).The objective of this study was to determine if treatment with donepezil, an acetylcholinesterase inhibitor, may provide benefit for VaD patients. Methods: Combined analysis of 2 identical randomized, double-blind, placebo-controlled, 24-week studies involving 1,219 patients enrolled at 109 investigational sites in the USA, Europe, Canada and Australia. Patients were randomized to receive donepezil 5 mg/day (n = 406) or 10 mg/day (after brief titration; n = 421) or placebo (n = 392). Patients were assessed on cognition [Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS[-]cog), Mini-Mental State Examination (MMSE)], global function [Clinician’s Interview- Based Impression of Change plus (CIBIC[-]plus), Clinical Dementia Rating – Sum of the Boxes (CDR[-]SB)] and function [Alzheimer’s Disease Functional Assessment and Change Scale (ADFACS); instrumental activities of daily living (ADFACS[-]IADL)].Results:Both donepezil groups showed significant improvements in cognition compared with placebo (ADAS-cog, MMSE, p< 0.01). Significant global function benefits were seen on the CIBIC-plus in the 5 mg/day group (placebo vs. 5 mg/day, p < 0.001; vs. 10 mg/day, p = 0.006) and on the CDR-SB in the 10 mg/day group (placebo vs. 5 mg/day, p = 0.09; vs. 10 mg/day, p< 0.01). Significant functional benefits were also seen (ADFACS, placebo vs. 5 mg/day, p = 0.08; vs. 10 mg/day, p = 0.02; ADFACS-IADL, p < 0.05 for both donepezil groups). Donepezil was well tolerated, with low withdrawal rates due to adverse events. Conclusions: This combined analysis of the largest trial on VaD to date showed that donepezil-treated patients had significant benefits in cognition, global function and ability to perform IADL. Based on these findings and reported tolerability, donepezil should be considered as an important therapeutic element in the overall management of patients with VaD.

Overview

Integrity signals

Registry

Crossref · 10.1159/000088494

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 10.1001%2Fjama.277.11.925 · doi:10.1001/jama.277.11.925 · Paper page

Cited by

See all 141

Metadata

Authors
Román, G. C., Wilkinson, D. G., Doody, R. S., Black, S. E., Salloway, S. P., & Schindler, R. J.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Moorgreen Hospital (GB)
  • Baylor College of Medicine (US)
  • Sunnybrook Health Science Centre (CA)
  • Brown University (US)
  • Pfizer (United States) (US)
Venue
Dementia and Geriatric Cognitive Disorders
Publisher
S. Karger AG
Published
2005
Volume
20
Issue
6
Pages
338-344
ISSN
  • 1420-8008 (ISSN-L)
  • 1421-9824
OpenAlex
W2144769321
Cited by
141
References
25
Citations by year
2025: 1 · 2024: 3 · 2022: 3 · 2021: 5 · 2020: 33 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 2 · 2013: 10 · 2012: 3
FWCI
6.81
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Dementia and Geriatric Cognitive Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
donepezil, vascular dementia, acetylcholinesterase inhibitors, cognitive function, global function, instrumental activities of daily living, dose comparison, tolerability
MeSH terms
Donepezil, Activities of Daily Living, Aged, Cholinesterase Inhibitors, Clinical Protocols, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans, Male, Piperidines, Dementia, Vascular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.